StreetInsider.com News Articles

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing

Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development

Mon, 18 May 2026 09:00:00 -0400

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®.
Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis.
Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra.

MUMBAI, India, May 18, 2026 /PRNewswire/ -- Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing